ClinicalTrials.gg
Not yet recruitingNCT07205601Updated Aug 26, 2026

Study of Intracerebroventricular Injections of Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild-Moderate Alzheimer's Disease

A Phase 2 interventional study of RB-ADSC and Placebo in Alzheimer Disease, sponsored by Regeneration Biomedical, Inc.. Not yet recruiting. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Regeneration Biomedical, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
45 Years to 85 Years
Sex
All
01

Study summary

The goal of this Phase 2 clinical trial is to learn if repeated dosing of RB-ADSC (an investigational autologous cell product obtained from participant's own adipose tissue) enhances the positive preliminary results seen in Phase 1 for the of treatment for mild to moderate Alzheimer's Disease in adults. The clinical trial will also continue to evaluate the safety of repeated dosing of RB-ADSC. This study will primarily evaluate the effects of repeated dosing of RB-ADSC on cognitive performance compared to placebo control. Participants will receive RB-ADSC every 2 months for a total of 6 doses. Participants randomized into the placebo control group will have the option to cross over to receive treatment after completion of the primary phase of the study.

Read the detailed description

This is a randomized, placebo-controlled, dose range finding for safety and efficacy, Phase 2a U.S. multicenter study of repeated administration of RB-ADSC in participants with mild to moderate Alzheimer's Disease AD. RB ADSC consists of stem cells obtained from the participant's own adipose tissue by lipoaspirate that have been cultured and expanded outside the body, enriched for Wnt-activated cells, and prepared for administration into the same participant. An Ommaya reservoir, which is an intraventricular catheter system, will be implanted under the scalp for intraventricular administration of RB-ADSC.

Approximately 115 adult participants are expected to be enrolled in this Phase 2a study. Participants will be randomized at a 4:1 ratio of RB-ADSC treatment to placebo. Participants randomized into the RB-ADSC treatment arm will be subsequently randomized with a 1:1 ratio to a treatment dose level: low-dose RB-ADSC (2.5 x 10\^6 cells), and high-dose RB-ADSC (5.0 x 10\^6 cells), for an overall randomization scheme of 2:2:1.

RB-ADSC will be delivered intracerebroventricularly every 2 months via the previously implanted Ommaya reservoir for a treatment duration of 10 months (inclusive of 10th month; up to 6 injections in total). Participants will be followed for 6 months after the last administration. The primary and secondary objectives will evaluate the efficacy based on cognitive, functional and CSF biomarker (Phospho-Tau, Total Tau, AB-42) assessments. Additionally, safety evaluations, volumetric MRI (Neuro Quant®) assessment, and diagnostic imaging comparison (Amyloid PET) will be performed.

After completing the Month 12 evaluation, participants in the placebo arm will be allowed to cross over to receive RB-ADSC. Participants in the cross-over will be randomized to a treatment dose level (low dose or high dose) at a 1:1 ratio. Cross-over participants will receive RB-ADSC doses every 2 months for a treatment duration of 10 months.

02

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • AD
  • Autologous
  • Stem cells
  • Cell therapy
  • Alzheimer Disease
03

In context

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

This study's planned enrollment of 115 is above the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

Regeneration Biomedical, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥45 and ≤85 years of age
  • Mild to moderate AD diagnosis
  • FAST stage 4 or 5
  • 10-23
  • Amyloid PET scan centiloid score >30
  • ADmark® CSF analysis of ATI (\<1.0) and P-Tau (>60)
  • No tumors or other disease responsible for dementia
  • Participant otherwise in good general health
  • Written from participant or legal representative
  • Participant must have caregiver who separately meets specified inclusion/exclusion criteria for caregivers
  • Participant must be able to donate adequate amount of lipoaspirate to establish the final product

Exclusion criteria

Exclusion Criteria:

  • Taking prohibited medications
  • Prior cell therapy implantation
  • Existing ventriculoperitoneal shunts
  • Neurological disorders except AD
  • Psychiatric disorders such as schizophrenia, bipolar/unipolar depression, delirium
  • Drug or alcohol abuse in past 2 years
  • History of cancer within the past 5 years
  • No caregiver available to meet the inclusion criteria for caregivers
  • Involvement in other product clinical trial within the past 3 months for monoclonal antibodies, or 6 months for other investigational products
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
115 participants (estimated)

Study arms

  • Experimental
    RB-ADSC low dose

    Participants will receive repeated doses of 2.5x10\^6 RB-ADSC infused in the previously implanted Ommaya reservoir

    Biological: RB-ADSC

  • Experimental
    RB-ADSC high dose

    Participants will receive repeated doses of 5x10\^6 RB-ADSC infused in the previously implanted Ommaya reservoir

    Biological: RB-ADSC

  • Placebo comparator
    Placebo control

    Participants will receive placebo comparator in the previously implanted Ommaya reservoir

    Other: Placebo

Interventions

  • BiologicalRB-ADSC

    RB-ADSC is an investigational an ex-vivo expanded autologous adipose-derived stem cell product

  • OtherPlacebo

    0.9% NaCl USP

06

What researchers measure

Primary outcomes

  1. Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) Composite Score

    iADRS will be used to assess whether RB-ADSC slows down the clinical decline associated with AD compared with placebo. iADRS evaluates cognition and daily function performance by combining items from the ADAS-Cog13 and the Alzheimer's disease cooperative study-instrumental activities of daily living scale (ADCS-iADL). The scale ranges from 0 to 144, where lower scores indicate worse performance and higher score indicates better performance.

    Time frame: Baseline, Month 6 and Month 12

Secondary outcomes

  1. Change from Baseline in CSF Biomarkers

    CSF Biomarkers will be measured with the ADmark® phospho-tau/total-tau/ Abeta-42 assay to determine the levels of Phosphorylated-Tau protein, Total-Tau protein, and Ab42 in the cerebrospinal fluid (CSF). The amyloid-tau index (ATI) will also be determined.

    Time frame: Baseline, Month 6 and Month 12

  2. Change from Baseline in MMSE

    Cognitive function will be evaluated with the Mini Mental State Examination (MMSE). The range for the total MMSE score is 0 to 30, with lower scores indicating greater level of impairment.

    Time frame: Baseline, Month 6 and Month 12

  3. Change from Baseline in ADAS-cog13

    Cognitive function will be assessed using the AD Assessment Scale - Cognitive (ADAS-cog13). The ADAS-Cog13 scale ranges from 0 to 85, with higher scores indicating greater disease severity.

    Time frame: Baseline, Month 6 and Month 12

  4. Change from Baseline in FAST

    Functional abilities will be assessed using the Functional Assessment Staging Tool (FAST). The tool consists of seven stages, with higher scores indicating more severe impairment.

    Time frame: Baseline, Month 6 and Month 12

  5. Change from Baseline in ADCS-iADL

    Functional ability will be assessed using the AD Cooperative Study-Activities of Daily Living Scale (ADCS-ADL). The iADL score ranges from 0 to 59, with lower scores indicating greater impairment.

    Time frame: Baseline, Month 6 and Month 12

  6. Change from Baseline in CDR-SB

    Cognitive changes will be assessed with the Clinical Dementia Rating - Sum of Boxes (CDR-SB). Scores range from 0 to 18 with higher scores indicative of more impairment.

    Time frame: Baseline, Month 6 and Month 12

  7. Change from Baseline in Amyloid Positron Emission Tomography (Amyloid-PET)

    Amyloid-PET will be used to quantitatively assess amyloid plaque deposition in the brain

    Time frame: Baseline, Month 6 and Month 12

  8. Change from Baseline in Volumetric MRI with Contrast

    Volumetric MRI with contrast of the brain will be used to detect and monitor brain abnormalities.

    Time frame: Baseline, Month 6 and Month 12

  9. Change from Baseline in NeuroQuant MRI

    NeuroQuant MRI will be used to measure volumes of brain structures.

    Time frame: Baseline, Month 6 and Month 12

  10. Safety of Repeated Dosing RB-ADSC

    Safety will be determined by the number of treatment-related adverse events (AE) and serious adverse events (SAE) graded according to CTCAE v5.0 up to Month 16 compared to placebo control

    Time frame: Up to Month 16

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Feb 2029, 28 months later.

Of 130 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 28 months is close to that.

Counting every sponsor, half of 257 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2025
First posted
Oct 3, 2025
StartEst.
Oct 2026
Primary completionEst.
Feb 2029
CompletionEst.
Feb 2030
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07205601
Lead sponsor
Regeneration Biomedical, Inc.
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Oct 2026 (estimated)
Primary completion
Feb 2029 (estimated)
Completion
Feb 2030 (estimated)
Last update
Aug 26, 2026

Study contacts

Robert Lynn
Contact
robert@regenerationbiomedical.com
877-240-1660

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion